Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survey quantifies COVID-19’s impact on oncology

Publish date:: September 20, 2020

Key clinical point: An international survey provides new insights into how COVID-19 has affected, and may continue to affect, the field of oncology.

Major finding: About 82% of oncologists surveyed said they were likely to continue the use of telemedicine in the future, but 45% said virtual international conferences are not an acceptable alternative to live conferences.

Study details: A survey of 109 oncologists in 18 countries, with answers recorded between June 17 and July 14, 2020.

Disclosures: The research was funded by Fondation Léon Fredericq. Dr. Jerusalem disclosed relationships with Novartis, Roche, Lilly, Pfizer, Amgen, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, AbbVie, MedImmune, and Merck.

Citation:

Jerusalem G et al. ESMO 2020, Abstract LBA76_PR.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,